CYP2C8 and lung adenocarcinoma: Of the 17 lung adenocarcinoma samples, 7 displayed an increase in CYP2C8 and/or CYP3A4 genes (multiplication of CYP2C8 in 1 sample, of CYP3A4 in 3, and of both CYP2C8 and CYP3A4 in 3 samples), predicting elevated paclitaxel-metabolizing capacity of these tumours (OK18 was excluded because he was under non-paclitaxel therapy).